Related Experiment Video

Updated: Jun 4, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer

José Baselga1

  • 1Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. jbaselga@partners.org

The Oncologist
|February 1, 2011
PubMed

Insights

The phosphoinositide-3 kinase (PI3K) pathway is crucial for breast cancer growth and metabolism. Targeting this pathway with new drugs shows promise for overcoming treatment resistance, but combination therapies may be needed.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The phosphoinositide-3 kinase (PI3K) pathway is a critical regulator of cancer cell metabolism and growth.
  • Aberrant PI3K pathway signaling is frequently observed in breast cancer, contributing to treatment resistance.
  • While recognized in research, the PI3K pathway's clinical relevance is emerging for breast cancer management.

Purpose of the Study:

  • To review current data on the PI3K pathway in breast cancer.
  • To discuss the role of PI3K pathway mutations in treatment resistance.
  • To explore the clinical implications of targeting the PI3K pathway in breast cancer.

Main Methods:

  • Literature review of current data on the PI3K pathway.
  • Analysis of PI3K pathway's role in breast cancer metabolism and growth.
  • Examination of PI3K pathway mutations and associated drug resistance.
  • Overview of available and investigational agents targeting the PI3K pathway.

Main Results:

  • PI3K pathway mutations are common in breast cancer.
  • These mutations can confer resistance to HER2-targeted and hormonal therapies.
  • Various agents targeting PI3K, Akt, and mTOR are under development.
  • Combination strategies may be necessary to overcome feedback loops and enhance efficacy.

Conclusions:

  • The PI3K pathway is a significant therapeutic target in breast cancer.
  • Understanding PI3K pathway alterations is key to developing effective treatments.
  • Investigational PI3K-targeting agents offer potential for improved breast cancer management, possibly in combination therapies.

More Related Videos

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
IP3/DAG Signaling Pathway01:11

IP3/DAG Signaling Pathway

Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the  phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and produces two-second...